题 目:Leveraging Nature’s Chemical Diversity for Drug Discovery
主讲人:Guy Carter(Biosortia Pharmaceuticals)
时 间:2016年10月26日(星期三)15:30-16:30
地 点:朝晖校区新教1202
讲座内容简介(Abstract):
Nature was known as a prolific source of medicines for thousands of years before the emergence of the pharmaceutical industry. Natural products achieved their highest impact in modern drug discovery during the “Golden Age” of antibiotics discovery from 1940 through the 1960’s. Since that time the use of natural products in drug discovery in the pharmaceutical industry has gradually declined as new paradigms featuring only synthetic chemistry have become dominant. However, in critical areas such as infectious diseases and cancer, synthetic chemistry has had limited success in developing new therapeutic agents, which has led to renewed interest in natural products. This presentation will focus on current methods of natural product utilization in drug discovery, including screening for leads as well as examples of lead optimization by medicinal chemistry.
主讲人简介:
Guy Carter博士,Biosortia制药公司的首席科学家。Carter博士1976年在University of Wisconsin获得生物化学博士学位。随后在University of Illinois从事博士后工作;曾任美国Pfizer/Wyeth公司的副总裁,负责天然药物的研发,主要通过化学分离和基因工程来全方位研究生物多样性、微生物、发酵等。现担任Biosortia制药公司的首席科学家,研究方向为源于微藻的天然产物药物的开发;兼Carter-Bernan咨询公司的CEO,专门提供微生物中天然药物研发的化学及微生物专业知识与技能。Carter 博士发现了微生物天然产物nemadectin,一种抗寄生虫药,上市后商品名为Moxidectin?,至今其在现有的人类疾病临床发展有充分的优势;还发现了微生物产物dioxapyrrolomycin,是吡咯杀虫剂系列新药物的奠基,并开发成为产品Pirate。
此外,其也是最初引领抗菌药物mannopeptimycins的优化,以开发出治疗多耐药性的格兰氏阳性菌的药物;又建立涵盖了生物合成化学及化bbin电子物功能的现代、技术向导的微生物天然产物的开发流程;以及与一些跨国学术团体合作,以促进联合药物的开发项目。最前列的是University of Utah、Papua New Guinea 和Fiji之间的合作。目前,Carter博士已获得美国专利21个,发表SCI论文120余篇;也担任Journal of Antibiotics,Journal of Natural Products,Antimicrobial Agents and Chemotherapy 以及Natural Products Reports等多个国际杂志的审稿人;于2008年出任美国社会执行委员会主席;还参与和组织了多个国际知名学术会议,如European Conference on Marine Natural Products等,以及担任2010年Gordon Research Conference、2012年International Conference on Natural Products Research等会议的主席。